Skip to main content

Press releases View all 7 hits

Sobi™ publishes its report for the first quarter 2016

Sobi™ publishes its report for the first quarter 2016

Press releases   •   Apr 27, 2016 06:00 UTC

Sobi™ today announced its results for the first quarter 2016. Revenue for the quarter totalled SEK 1,273 M (865), an increase of 47 per cent compared to previous year. All parts of the business contributed to the result with Orfadin® and Kineret® delivering strong performance.

Sobi announces commercial launch of Elocta® in first countries in Europe

Sobi announces commercial launch of Elocta® in first countries in Europe

Press releases   •   Jan 11, 2016 07:00 UTC

Sobi today announced the commercial launch of Elocta® (efmoroctocog alfa) in first countries in Europe. Elocta is a recombinant human factor VIII Fc fusion protein with an extended half-life, and is the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.

Sobi and Biogen’s Elocta® (rFVIIIFc) approved in Europe for the treatment of haemophilia A

Press releases   •   Nov 24, 2015 07:47 UTC

Sobi and Biogen today announced that the European Commission (EC) has approved Elocta® (rFVIIIFc) for the treatment of haemophilia A in all 28 European Union (EU) member states, as well as Iceland, Liechtenstein and Norway. Elocta will be the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.

Extension study data supporting long-term safety and efficacy of Eloctate®/Elocta® published in Haemophilia

Press releases   •   Aug 10, 2015 11:06 UTC

Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with Eloctate®/Elocta® (rFVIIIFc) experienced low bleeding rates. Interim results show participants maintained low bleeding rates with prophylactic dosing.